Recaticimab plus standard therapy: Clinical Trials

1 not yet recruiting. 1 Phase 4.

By phase and status

Phase	Trials	Status
Phase 4	1	Not yet recruiting 1

Follow Recaticimab plus standard therapy: new trials by email Literature Review of Recaticimab plus standard therapy trials Research Report on Recaticimab plus standard therapy

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke Recaticimab plus standard therapy, Recaticimab's placebo in combination with standard therapy - Acute Ischemic Stroke AIS, Intracranial Atherosclerosis ICAS	Phase 4	Not yet recruiting	Peking Union Medical College Hospital	1212	2026-09-01	2026-07-15

Conditions studied

Intracranial Arteriosclerosis (1)  ·  Plaque, Atherosclerotic (1)

Sponsors

Peking Union Medical College Hospital (1)

Countries

China (1)

Results publications

PMID 28304224, PMID 30066942, PMID 31707788, PMID 32561535, PMID 32817184, PMID 35048716, PMID 35143758, PMID 38048667, PMID 38212060, PMID 38648030, PMID 38817546, PMID 39387764, PMID 39505412, PMID 39548030, PMID 39755915, PMID 39818872, PMID 40616232, PMID 40820974, PMID 41107765, PMID 41389830, PMID 41500725, PMID 41582814, PMID 42262770